Free Trial

Hyperfine (NASDAQ:HYPR) Trading Up 12.7% - What's Next?

Hyperfine logo with Medical background

Hyperfine, Inc. (NASDAQ:HYPR - Get Free Report) shares were up 12.7% during mid-day trading on Monday . The stock traded as high as $1.27 and last traded at $1.24. Approximately 420,808 shares were traded during mid-day trading, an increase of 204% from the average daily volume of 138,523 shares. The stock had previously closed at $1.10.

Hyperfine Stock Performance

The company has a market cap of $118.18 million, a PE ratio of -2.84 and a beta of 0.92. The stock's 50-day simple moving average is $1.00 and its 200 day simple moving average is $1.01.

Hyperfine (NASDAQ:HYPR - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). Hyperfine had a negative net margin of 309.42% and a negative return on equity of 57.54%. The firm had revenue of $3.64 million during the quarter, compared to analysts' expectations of $3.40 million. During the same period in the prior year, the company posted ($0.15) earnings per share. On average, sell-side analysts predict that Hyperfine, Inc. will post -0.57 EPS for the current fiscal year.

Institutional Trading of Hyperfine

An institutional investor recently bought a new position in Hyperfine stock. Graypoint LLC bought a new position in shares of Hyperfine, Inc. (NASDAQ:HYPR - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 50,000 shares of the company's stock, valued at approximately $44,000. Graypoint LLC owned approximately 0.07% of Hyperfine as of its most recent filing with the SEC. 15.03% of the stock is currently owned by institutional investors.

About Hyperfine

(Get Free Report)

Hyperfine, Inc, a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors.

Recommended Stories

Should You Invest $1,000 in Hyperfine Right Now?

Before you consider Hyperfine, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hyperfine wasn't on the list.

While Hyperfine currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines